Skip to main content

Advertisement

SpringerLink
Log in

Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients

  • Original article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Cytokine-induced killer (CIK) cells show cytolytic activity against tumor. The purpose of this study was to evaluate the antitumor effect of dendritic cell (DC)-activated CIK cells in vitro and their clinical efficacy of DC-activated CIK cells in combination with chemotherapy (abbreviated below as chemotherapy plus DC + CIK) in patients with advanced non-small-cell lung cancer (NSCLC). A paired study was performed between 61 patients treated with chemotherapy alone (group 1) and 61 patients treated with chemotherapy plus DC + CIK cells (group 2). In group 2, 36 patients with adenocarcinoma and 18 patients with squamous cell carcinoma were analyzed for the survival rate. Compared to unstimulated CIK cells, DC-activated CIK cells significantly enhanced antitumor activity, increased the ratio of CD3+CD56+ cells, promoted cell proliferation and lessened cell apoptosis. In the paired study, the 1- and 2-year overall survival rates in group 2 were 57.2 and 27.0 %, which were significantly higher than that of group 1 (37.3 and 10.1 %) (P < 0.05). There was no significant difference in the survival rate between the adenocarcinoma and squamous carcinoma patients in group 2. The present study suggests that DC-activated CIK cell has enhanced antitumor effects and chemotherapy plus DC + CIK cells improved the clinical outcomes of chemotherapy for advanced NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rosti G, Carminati O, Monti M, Tamberi S, Marangolo M (2006) Chemotherapy advances in small cell lung cancer. Ann Oncol 17(Suppl 5):v99–v102

    Article  PubMed  Google Scholar 

  2. Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11:1866–1872

    PubMed  CAS  Google Scholar 

  3. Choudhury A, Palma M, Mellstedt H (2008) The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. Clin Lung Cancer 9(Suppl 1):S37–S44

    Article  PubMed  CAS  Google Scholar 

  4. Mac Manus MP, Matthews JP, Wada M, Wirth A, Worotniuk V, Ball DL (2006) Unexpected long-term survival after low-dose palliative radiotherapy for non-small cell lung cancer. Cancer 106:1110–1116

    Article  PubMed  Google Scholar 

  5. Penland SK, Socinski MA (2004) Management on unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. Semin Radiat Oncol 14:326–334

    Article  PubMed  Google Scholar 

  6. Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T, Schmidt-Wolf IG (2001) Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 24:502–510

    Article  PubMed  Google Scholar 

  7. Zhang YS, Yuan FJ, Jia GF, Zhang JF, Hu LY, Huang L, Wang J, Dai ZQ (2005) CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 11:3339–3345

    PubMed  Google Scholar 

  8. Ren X, Yu J, Liu H, Zhang P, An X, Zhang N, Hao X (2006) Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biother Radiopharm 21:22–33

    Article  PubMed  CAS  Google Scholar 

  9. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139–149

    Article  PubMed  CAS  Google Scholar 

  10. Verneris MR, Kornacker M, Mailänder V, Negrin RS (2000) Resistance of ex vivo expanded CD3 + CD56 + T cells to Fas-mediated apoptosis. Cancer Immunol Immunother 49:335–345

    Article  PubMed  CAS  Google Scholar 

  11. Lu PH, Negrin RS (1994) A novel population of expanded human CD3 + CD56 + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153:1687–1696

    PubMed  CAS  Google Scholar 

  12. Scheffold C, Brandt K, Johnston V, Lefterova P, Degen B, Schöntube M, Huhn D, Neubauer A, Schmidt-Wolf IG (1995) Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant 15:33–39

    Article  PubMed  CAS  Google Scholar 

  13. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS (2005) A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:181–187

    Article  PubMed  Google Scholar 

  14. Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, Han Y, Ren XB (2009) Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 11:1076–1083

    Article  PubMed  CAS  Google Scholar 

  15. Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81:1009–1016

    Article  PubMed  CAS  Google Scholar 

  16. Fields RC, Shimizu K, Mulé JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95:9482–9487

    Article  PubMed  CAS  Google Scholar 

  17. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  PubMed  CAS  Google Scholar 

  18. Wu C, Jiang J, Shi L, Xu N (2008) Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 28:3997–4002

    PubMed  CAS  Google Scholar 

  19. Herberman RB (1987) Cancer therapy by biological response modifiers. Clin Physiol Biochem 5:238–248

    PubMed  CAS  Google Scholar 

  20. Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, Nash RA, Aglietta M, Cignetti A (2008) Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 20:841–848

    Article  PubMed  CAS  Google Scholar 

  21. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG (2011) Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137:305–310

    Article  PubMed  CAS  Google Scholar 

  22. Gallimore A, Godkin A (2008) Regulatory T cells and tumour immunity—observations in mice and men. Immunology 123:157–163

    Article  PubMed  CAS  Google Scholar 

  23. Li H, Yu JP, Cao S, Wei F, Zhang P, An XM, Huang ZT, Ren XB (2007) CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol 27:317–326

    Article  PubMed  CAS  Google Scholar 

  24. Wahl SM, Wen J, Moutsopoulos N (2006) TGF-beta: a mobile purveyor of immune privilege. Immunol Rev 213:213–327

    Article  PubMed  CAS  Google Scholar 

  25. Galliher AJ, Neil JR, Schiemann WP (2006) Role of transforming growth factor-beta in cancer progression. Future Oncol 2:743–763

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant from major scientific and technological project of Science and Technology Commission Foundation of Tianjin (No. 043115211-2) and Health Department Fund project of Tianjin (No. 09KZ80).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Immunology, Tianjin Cancer Institute & Hospital, Tianjin Medical University, Huanhuxi Road, Tiyuanbei, Hexi District, 300060, Tianjin, China

    Lili Yang, Baozhu Ren, Hui Li, Jinpu Yu, Shui Cao, Xishan Hao & Xiubao Ren

  2. Research Center of Lung Cancer, Tianjin, China

    Lili Yang, Baozhu Ren, Hui Li, Jinpu Yu, Shui Cao, Xishan Hao & Xiubao Ren

Authors
  1. Lili Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baozhu Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jinpu Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shui Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xishan Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiubao Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xishan Hao or Xiubao Ren.

Additional information

Lili Yang and Baozhu Ren contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, L., Ren, B., Li, H. et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 62, 65–73 (2013). https://doi.org/10.1007/s00262-012-1311-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-012-1311-8

Keywords

Search

Navigation